Grifols Egypt for Plasma Derivatives (GEPD) is a joint‑venture between the Egyptian Government’s National Service Projects Organization and the global plasma medicines leader Grifols. The company is building 20 plasma donation centers across Egypt and a state‑of‑the‑art manufacturing complex that can process up to 1 million liters of plasma per year, with the capacity to double in the future. As the first Egyptian source member of the Plasma Protein Therapeutics Association, GEPD is pioneering a public‑private alliance that will drive regional self‑sufficiency in critical plasma‑derived therapies. Its integrated approach—combining collection, fractionation, purification, and fill‑and‑finish operations—positions GEPD as a key player in improving access to high‑quality plasma medicines for the Egyptian healthcare system.
Responsible for leading and managing the organization's safety program, creating a safe and compliant work environment by developing and implementing safety policies, procedures, and initiatives.
Grifols Egypt for Plasma Derivatives (GEPD) is a joint‑venture between the Egyptian Government’s National Service Projects Organization and the global plasma medicines leader Grifols. The company is building 20 plasma donation centers across Egypt and a state‑of‑the‑art manufacturing complex that can process up to 1 million liters of plasma per year, with the capacity to double in the future. As the first Egyptian source member of the Plasma Protein Therapeutics Association, GEPD is pioneering a public‑private alliance that will drive regional self‑sufficiency in critical plasma‑derived therapies. Its integrated approach—combining collection, fractionation, purification, and fill‑and‑finish operations—positions GEPD as a key player in improving access to high‑quality plasma medicines for the Egyptian healthcare system.